文献速递前列腺癌

全腺体或次全高能聚焦超声对比根治性前列腺切除术:前瞻性、非劣效、非随机HIFI试验

Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial.
PubMed 文献 · Eur Urol · 2024-12-04

法国46中心前瞻性非随机试验纳入低至中危前列腺癌3328例(HIFU组1967例,RP组1361例),30个月无挽救治疗生存率HIFU组不劣于RP组(HR 0.71,95%CI 0.52-0.97;p=0.008)。HIFU组12个月尿控恶化比例更低(29% vs 44%),国际勃起功能指数-5评分下降幅度更小(差值-7 vs -13)。

要点

  • HIFU组30个月无挽救治疗生存不劣于RP组(HR 0.71,95%CI 0.52-0.97;p=0.008)。
  • HIFU组12个月尿控恶化29% vs RP组44%,IIEF-5评分下降差值-7 vs -13。
  • HIFU组约10%患者发生尿潴留,>IIIa级并发症54/1967例 vs RP组29/1361例(p=0.3)。

核心结论

  • 这项大型前瞻性试验表明,全腺体或次全HIFU提供与RP相当的中期无挽救治疗生存结局。
  • HIFU后尿控和勃起功能受损更轻。
  • 由于缺乏随机化和组间年龄差异,这些结果应谨慎解读。
  • 未来研究应考虑更长随访并评估局灶治疗。

研究设计与样本

  • 法国46个中心的前瞻性非随机全国性试验,比较根治性前列腺切除术(RP)与高能聚焦超声(HIFU)。
  • 主要纳入标准为低至中危前列腺癌。
  • 2015年至2019年共纳入3328例患者(HIFU组1967例,RP组1361例)。
  • 主要终点为无挽救治疗生存(STFS);次要终点为无转移生存、前列腺癌特异性生存、总生存和功能结局。
  • 试验在ClinicalTrials.gov注册为NCT04307056。

主要发现

  • HIFU组与RP组中位年龄分别为74.7岁与65.1岁(p<0.001),中位PSA分别为7.1与6.9 ng/ml(p=0.5)。
  • HIFU组61%和RP组64%诊断为中危前列腺癌(p=0.10)。
  • 30个月STFS在HIFU组不劣(风险比0.71,95%置信区间0.52-0.97;p=0.008)。
  • HIFU后约10%患者发生尿潴留;>IIIa级并发症HIFU组54/1967例 vs RP组29/1361例(p=0.3)。
  • HIFU组12个月尿控恶化患者更少(29% vs 44%),中位国际勃起功能指数-5评分下降更小(差值-7 vs -13);国际前列腺症状评分和生活质量评分两组相当。

局限性

  • 主要局限性为缺乏随机化和组间年龄差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: High-intensity focused ultrasound (HIFU) has emerged as an interesting ablative alternative to radical prostatectomy (RP) and radiation therapy (RT) for localized prostate cancer (PC). However, no prospective comparative data have been published for HIFU. METHODS: We performed a prospective nonrandomized nationwide trial in 46 centers in France comparing RP versus HIFU. The main inclusion criterion was low- to intermediate-risk PC. The primary endpoint was salvage therapy-free survival (STFS). Secondary endpoints were metastasis-free survival, PC-specific survival, overall survival, and functional outcomes. KEY FINDINGS AND LIMITATIONS: From 2015 to 2019, 3328 patients were included (1967 HIFU and 1361 RP). Median age was 74.7 versus 65.1 yr (p < 0.001) and median PSA was 7.1 versus 6.9 ng/ml (p = 0.5) in the HIFU and RP groups, respectively. Intermediate-risk PC was diagnosed in 61% of patients in the HIFU group and 64% in the RP group (p = 0.10). The 30-mo STFS was not inferior in the HIFU group (hazard ratio 0.71, 95% confidence interval 0.52-0.97; p = 0.008). Some 10% of patients experienced urinary retention after HIFU. Grade >IIIa complications occurred in 54/1967 cases in the HIFU group and 29/1361 cases in the RP group (p = 0.3). In the HIFU group, fewer patients experienced a deterioration in 12-mo urinary continence (29% vs 44%) and the decrease in median International Index of Erectile Function-5 score was lower (difference -7 vs -13) in comparison to RP. Internal Prostate Symptom Scores and quality-of-life scores were comparable in the two groups. The main limitations are the lack of randomization and the age difference between the groups. CONCLUSIONS AND CLINICAL IMPLICATIONS: This large prospective trial demonstrates that whole-gland or subtotal HIFU provides comparable medium-term STFS outcomes to RP. Urinary continence and erectile function were less impaired after HIFU. These results should be interpreted with caution owing to the lack of randomization and the age difference between the groups. Future research should consider longer follow-up and evaluate focal treatments. This trial is registered on ClinicalTrials.gov as NCT04307056.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Ploussard G, Coloby P, Chevallier T, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. 2024. PMID: 39632125. doi:10.1016/j.eururo.2024.11.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。